Astrazeneca Fulvestrant CAS 129453-61-8 Faslodex Hormone for Breast Cancer Treatment
Fulvestrant
Quick Details:
CAS No.:129453-61-8
Other Names:Faslodex
MF:C32H47F5O3S
EINECS No.:N/A
Place of Origin:ShenZhen, China (Mainland)
Type:Antineoplastic Agents
Grade Standard:Medicine Grade
Brand Name: SENDI
Model Number:BP/EP/USP
Purity:99.99%
Molecular Weight::606.77
Density::1.201 g/cm3
Boiling Point::674.8 °C at 760 mmHg
Flash Point::361.9 °C
Fulvestrant is a drug treatment of hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following anti-estrogen therapy. It is an estrogen receptor antagonist with no agonist effects, which works both by down-regulating and by degrading the estrogen receptor. It is administered as a once-monthly injection.
Description:
Fulvestrante (Faslodex, AstraZeneca) is a drug treatment of hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following anti-estrogen therapy. It is an estrogen receptor antagonist with no agonist effects, which works by down-regulating the estrogen receptor.
Fulvestrante is a selective estrogen receptor down-regulator (SERD). Fulvestrante is indicated for the treatment of hormone receptor positive metastatic breast cancer in postmenopausal women with disease progression following anti-estrogen therapy. The dosing schedule for fulvestrante remains under investigation in an attempt to optimize its effectiveness.
Fulvestrante provided effective second-line therapy in this setting for postmenopausal women who had relapsed or progressed after previous endocrine therapy.
COA:
Test Item | Specification | Results | |
Appearance | A white to off-white crystalline powder | A white crystalline powder | |
Identification | The retention time of the major peak in the chromatogram of the assay preparation is same as that of the standard preparation obtained in the assay | Conform | |
Any Individual impurity | Not more than 0.10% | 0.18% | |
Total impurities | Not more than 1.0% | 0.44% | |
Ratio of isomers | 50.0%-60.0% | 51.70% | |
40.0%-50.0% | 47.86% | ||
purity | 99.0% | 99.99% | |
Description:
Faslodex is a drug treatment of hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following anti-estrogen therapy. It is an estrogen receptor antagonist with no agonist effects, which works both by down-regulating and by degrading the estrogen receptor. It is administered as a once-monthly injection.
Faslodex is a type of hormone treatment.It is a treatment for post menopausal women with advanced breast cancer.A novel steroidal estrogen antagonist reported to lack any partial agonist activity. Also used as an antineoplastic raw materials.
Application:
Faslodex( AstraZeneca) is a drug treatment of hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following anti-estrogen therapy. It is an estrogen receptor antagonist with no agonist effects, which works by down-regulating the estrogen receptor.
Faslodex is a selective estrogen receptor down-regulator (SERD). Faslodex is indicated for the treatment of hormone receptor positive metastatic breast cancer in postmenopausal women with disease progression following anti-estrogen therapy. The dosing schedule for Faslodex remains under investigation in an attempt to optimize its effectiveness.
Faslodex provided effective second-line therapy in this setting for postmenopausal women who had relapsed or progressed after previous endocrine therapy.
In particular 4 clinical trials in this setting did show similar efficacy to the other hormonal agents (aromatase inhibitors and tamoxifen a) with good tolerability profile. Faslodex had a lower incidence of joint disorders.
Many breast cancers are stimulated to grow by the female sex hormones oestrogen and progesterone. These breast cancers are called hormone sensitive or hormone receptor positive. Drugs that block the effects of these hormones can slow or stop the growth of the breast cancer cells. Faslodex stops oestrogen getting to the cancer cells by blocking oestrogen receptors and reducing the number of receptors the cancer cell has.
The quality control process:
1)Purchasing
Thorough market research, understand the price of raw materials and performance.To the procurement source to understand fully, and fully guarantee the quality of the procurement of raw materials.
2) Inspection
Four steps: sampling, sample pretreatment, measuring and data processing.
3) Producing
a)Each operator must do self-inspection of products and make the corresponding inspection records.
b)Full-time inspectors through check the operator self-inspection, and review and sign in the corresponding record. Full-time inspection is responsible for inspection of finished product, and make the finished product incoming inspection records.
4) Before selling
Test result can be provided before selling.
Third-party detection institution is allowed if you are not satisfied with test results.
